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Abstract
OBJECTIVE: To systematically research the post-
marketing safety of Dengfeng® shenmai injection,
identify potential risk factors, and ensure its clinical
safety.
METHODS: We investigated a comprehensive se-
ries of studies on the production process, quality
standards, pharmacology, postmarketing clinical
studies, and safety evaluation of Shenmai injection,
including literature analysis of adverse drug reac-
tion (ADR) case analysis and systematic review. Da-
ta from the hospital information system (HIS) and
spontaneous reporting system (SRS) were also ana-
lyzed.
RESULTS: The approximate dosage leading to
death in dogs is 45.0-67.5 g raw drug/kg and the
toxic reactions are restlessness, skin irritation, sali-
vation, and vomiting. The results of chronic toxicity
tests in mice and dogs, and the other tests such as
6-month toxicity, drug safety, genetic toxicity, and
reproductive toxicity of rats and dogs, were posi-
tive or qualified. Patient ADR history and ADR fami-
ly history were closely associated with itching
based on the data analysis from SRS. There was no
damage to renal function from Shenmai injection
use at a dosage and a treatment course outside the
recommended dosage and treatment course as
specified based on data analysis from HIS. The most
common ADR from Shenmai injection are difficulty
breathing, facial flushing, nausea, vomiting, chest
tightness, skin itching, rash, and back pain.
CONCLUSION: This study includes complete infor-
mation on Shenmai injection ADR incidence rate.
We found that Shenmai injection is safe and this
study can provide clinical, research, and production
institutions with an objective, reliable, and scientif-
ic basis for use of Shenmai injection.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Shenmai injection is a Chinese medicine injection orig-
inating from the ancient formula Shengmaisan. The
formula was reformed by modern technology based on
the ancient formula shendongyin recorded in Zheng
Yin Mai Zhi Volume Ⅱ by Jingming Qin in the Ming
Dynasty.1 Today the Shenmai injection on the market
is provided with seven specifications and 33 license
numbers contributed by seven manufacturers.
This study investigates only Dengfeng® shenmai injec-
tion made by Chiatai Qingchunbao Pharmaceutical
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Co. Ltd. (CTQ, Hangzhou, China). Dengfeng® shen-
mai injection is made from Hongshen (Radix Ginseng
Rubra) and Maidong (Radix Ophiopogonis Japonici)
from Zhejiang, China. The injection can benefit Qi to
prevent exhaustion, nourish Yin to generate body fluid,
and promote pulse. It is usually used to treat shock,
coronary heart disease, viral myocarditis, chronic pul-
monary heart disease, and neutropenia. In addition, it
can improve the immunity of cancer patients and can
be used as an adjunct to chemotherapy, while reducing
toxic adverse reactions. Its adverse reactions include oc-
casional allergic reactions.
Since its introduction to the market in 1986, this injec-
tion has been widely used clinically. CTQ carried out a
comprehensive series of studies on the production pro-
cess, quality standards, pharmacology, postmarketing
clinical studies, and safety evaluation, to continuously
improve effectiveness, safety, and control of drug quali-
ty. These studies ensure clinical safety and effectiveness,
and identify potential risk factors of the drugs as early
as possible to further improve drug safety.
MEDICINE QUALITY CONTROL
Quality control of raw herbal medicinal material
Dengfeng® shenmai injection is made from Hongshen
(Radix Ginseng Rubra) and Maidong (Radix Ophiopogo-
nis Japonici). The Hongshen (Radix Ginseng Rubra) is
supplied by a certified manufacturer of Chinese crude
drugs by the National good manufacturing practice
(GMP), which is involved in the planting and process-
ing of ginseng. Maidong (Radix Ophiopogonis Japonici)
is supplied by the planting base of CTQ, which is certi-
fied by good agriculture practice (GAP) in Cixi, Zheji-
ang, China.
Quality control of the production process
CTQ collected data from different batches, developed
scientific and reasonable process specifications, and per-
formed a systemic workmanship study on the processes
of extraction, purification, decolorization, alcohol re-
moval, and ultrafiltration, to ensure the uniformity
and stability of product quality.2 In 2011, CTQ intro-
duced fingerprint check items and formulated current
quality standards for Shenmai injection
(WS3-B-3428-98-2010Z). Furthermore, in addition
to the existing standards, CTQ developed rigorous in-
ternal control standards, which added the measure-
ment of borneol glycoside content, which is the charac-
teristic ingredient of Maidong (Radix Ophiopogonis Ja-
ponici). CTQ also added a series assay items like pro-
tein, resin, oxalate, potassium, total solids, ignition resi-
dues, arsenic salt, and heavy metals. The sampling
amount of the sterility test was increased, the injection
dose of heat source examination was added, and the re-
quirements for the content measurement of total ba-
icalin were raised. Additionally, ginsenoside rg1 and re
were added to existing content measurement items and
internal control standards adopted more stringent fin-
gerprinting technology for materials, intermediate
products, and finished products. For stability studies,
CTQ used high-temperature tests, glare tests, frozen
process experiments, low-temperature tests, retrospec-
tive analysis of finished product, retained samples, and
intermediate product, long-term stability studies (24
months), and acceleration tests. The projects of inspec-
tion include related substance inspection, total ginseng
saponin content, fingerprinting, abnormal toxicity, he-
molysis and agglutination, and heavy metals. Interme-
diate internal control standards were established with
satisfactory results. Study on the compatibility of Shen-
mai injection and drugs commonly used in clinic
found that: 5% dextrose injection, 10% dextrose injec-
tion, dextrose and sodium chloride injection, 0.9% so-
dium chloride injection, and 22 other kinds of medi-
cines are suitable for application in combination with
Shenmai injection at various specifications.
Studies on non-clinical safety and pharmacology
In 2009, CTQ authorized a safety evaluation research
center at Zhejiang Academy of Medical Sciences (Zheji-
ang, China) to perform non-clinical safety studies on
Dengfeng® shenmai injection. General pharmacology
studies, chronic toxicity tests in mice and dogs after in-
travenous injection, 6-month toxicity, drug safety, ge-
netic toxicity, and reproductive toxicity of rats and
dogs after intravenous injection were comprehensively
investigated.3
For the acute toxicity tests, the dosage of Dengfeng®
shenmai injection tolerable to mice is 40 g raw drug/
kg. The approximate dosage leading to death of beagle
dogs is: 45.0-67.5 g raw drug/kg.
For chronic toxicity tests, beagles were given 20, 6, and
3 g of Dengfeng® shenmai injection intravenously for 6
months. Toxic reactions such as restlessness, skin irrita-
tion, salivation, and vomiting occurred.
For tests on genetic toxicity, undue toxicity, irritation,
allergies, and hemolysis, the results were positive or
qualified. Genetic toxicity tests include reproductive
and early embryonic developmental toxicity tests on
rats with the rat embryo-fetal developmental toxicity
test. The results showed that some maternal toxicity
and mild embryo-fetal developmental toxicity ap-
peared in the SD rat groups receiving 20, 6, and 3 g
raw drug/kg-1·d-1. However, there was no maternal tox-
icity or embryo developmental toxicity found in the
groups receiving 2 g raw drug/kg-1·d-1.
In general pharmacological tests, there were no effects
on the nervous system or cognitive ability in mice re-
ceiving an intravenous dosage of 5, 15 g raw drug/kg.
However, the administration of 12, 3, and 1 g raw
drugs of Dengfeng® shenmai injection slowed the heart
rate of dogs until the 120 min after administration.
Then, the heart rate returned to normal. There were
no significant effects on each electrocardiogram indica-
tor, body temperature, or breathing rate of the dogs.
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In 2011, the concept "Network pharmacology for Chi-
nese medicine" was introduced in the National Key
Technological Project Technical Reform of Shenmai In-
jection (No. 2008ZX09202), and the network pharma-
cology of Dengfeng® shenmai injection was researched
for the first time. A gene regulating network model of
Dengfeng® shenmai injection for resisting myocardial
infarction in rats was built with gene and chip technol-
ogy, and its regulating effect was found in several signal
pathways such as the cell cycle, neurotransmitters, and
Wnt. This demonstrated the "multi-target and
multi-channel" effect of Dengfeng® shenmai injection.
This project provided a scientific basis for the establish-
ment of drug quality evaluation methods and guidance
for clinical use.
Postmarketing clinical safety studies
CTQ monitored ADR from Dengfeng® shenmai injec-
tion in cooperation with the Shanghai ADR Monitor-
ing Center, Zhejiang ADR Monitoring Center, and
Shanghai Production-Study-Research Cooperation
Project Team. From 2004-2009, Shanghai ADR Moni-
toring Center found 121 ADR from Shenmai injec-
tion (including combined medications), including
four severe ADR. Overall, 79 patients were relieved,
42 patients were cured, and no patients died or per-
manently worsened. According to estimates from the
digital data display system, the total incidence of
ADR from Shenmai injection is 0.014%, while the in-
cidence of serious ADR is 0.0058%. That means that
Shenmai injection is relatively safe. Since 2007, Zheji-
ang ADR Monitoring Center found 331 ADR and 23
severe ADR (6.95% ) from Dengfeng® shenmai injec-
tion. Overall, the vast majority ADR patients were
cured or relieved and no patient was died or experi-
enced a worsened condition. Most ADR are relatively
mild allergic reactions such as rash, fever, and chills.
All ADR were cured and improved after treatment or
drug withdrawal.
From February 2009 to December 2011, CTQ
launched the Postmarketing Intensive Monitoring
Study on Shenmai Injection in cooperation with the
Shanghai Production-Study-Research Cooperation
Project Team to research the clinical safety of Deng-
feng® shenmai injection. This was a prospective,
multi-center, open-label study and active observation
based on pharmacoepidemiology. The research was con-
ducted via questionnaires distributed by Shanghai
ADR Monitoring Center. Data were collected from 72
medical institutions in Shanghai, Anhui, and Zhejiang.
Overall, 20 924 cases were recorded. According to the
monitoring results of contract research organization,
18 ADR patients were reported with an incidence rate
of 0.086%. Based on ADR incidence classification stan-
dards, the ADR incidence rate as a result of the moni-
toring is classified as rare.
Since Dengfeng® injection entered the market, CTQ
has carried out effectiveness evaluation study with Zhe-
jiang Chinese Medical University, Thoracic Obstruc-
tion Emergency Collaborative Group of Division of
Medical Affairs, State Administration of Traditional
Chinese Medicine, and the Affiliated Hospital of
Guangzhou University of Traditional Chinese Medi-
cine. In the 1990s, Luming Liu of Zhejiang Chinese
Medical University studied the effect of Shenmai injec-
tion for increasing effectiveness and reducing toxicity
toward malignant cancers in chemotherapy. The results
showed that, combined with chemotherapy, Shenmai
injection significantly increased effectiveness while re-
ducing toxicity. In addition, patient immunity was im-
proved.
In 1996, an expanded clinical verification of Shenmai
injection was jointly carried out by 11 agencies includ-
ing Beijing Branch of Thoracic Obstruction Emergen-
cy Collaborative Group of Division of Medical Affairs,
State Administration of Traditional Chinese Medicine,
Ruijin Hospital Affiliated to Shanghai Second Medical
University, and Zhongshan Hospital Affiliated to
Shanghai Medical University. The research incorporat-
ed 1163 emergency cases of various types including
736 cases of cardiovascular disease. Results showed that
Shenmai injection has the following clinical effects:
Shenmai injection can significantly reduce the out-
break of coronary heart disease and angina, and relieve
the symptoms of chest choke, palpitations, shortness of
breath, fatigue and burning sensation of five centers
due to coronary heart disease. Shenmai injection can
improve a variety of arrhythmias and the symptoms of
chest choke, palpitations, dizziness, shortness of breath
due to arrhythmias. When used in combination with
conventional anti-heart failure drugs, Shenmai injec-
tion can significantly improve heart function in pa-
tients with congestive heart failure, shorten the time to
improving heart function, and improve symptoms in
patients with heart failure. Moreover, it is able to effec-
tively reduce the heart rate and blood pressure of heart
failure patients. When used in combination with con-
ventional anti-myocardial infarction drugs, Shenmai in-
jection can effectively control arrhythmias, and signifi-
cantly improve hypotension and heart failure induced
by acute myocardial infarction. The efficacy of Shen-
mai injection is much better than that of conventional
anti-myocardial infarction drugs used alone. For pa-
tients with acute exacerbation of pulmonary heart dis-
ease, Shenmai injection significantly improves remis-
sion rates of disease and improves blood analysis param-
eters, and oxygen and carbon dioxide levels return to
normal. Shenmai injection significantly relieves shock
due to allergic, infectious, or hemorrhagic events (in
particular shock due to cardiovascular events), and can
increase and stabilize blood pressure, and improve
symptoms of syncope. Shenmai injection can signifi-
cantly improve the therapeutic efficacy of acute pneu-
monia symptoms and shorten the number of days to
the disappearance of all signs compared with the use of
conventional anti-infection drugs alone.
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Postmarketing clinical trials on the treatment of
coronary heart disease and chronic heart failure
(deficiency of both Qi and Yin)
From 2010-2012, CTQ carried out postmarketing clin-
ical trials on the treatment of coronary heart disease
and chronic heart failure (Deficiency of both Qi and
Yin) with Dengfeng® shenmai injection. Parallel, dou-
ble-blind, randomized, and placebo controlled trials
were performed, which were the first double-blind
postmarketing clinical trials of a TCM injection. The
trials were conducted by professors Shaoxiang Xian
and Zhongqi Yang as principal researchers at the First
Affiliated Hospital of Guangzhou University of Chi-
nese Medicine in collaboration with seven sub-centers.
The trials showed that primary efficacy indicators such
as the efficacy on cardiac function and TCM syn-
dromes in the experimental group were better than
those in the control group. In addition, in the 6 min
walking test, the rate of patients with relief of severe
heart failure symptoms was far higher in the Shenmai
injection group than that in the control group. Safety
results showed that patients appeared in good medica-
tion compliance, and no ADR were found in the pa-
tients from the experimental group. Laboratory tests
showed no abnormalities in laboratory test indicators.
Therefore, Shenmai injection has good tolerability and
high safety for patients suffering chronic heart failure
and coronary heart disease.
Registry-based postmarketing clinical safety
monitoring study
Since November 2011, at the request of CTQ, Insti-
tute of Basic Research in Clinical Medicine, China
Academy of Chinese Medical Sciences carried out post-
marketing safety evaluation study. The postmarketing
safety evaluation study Registry-based intensive hospi-
tal monitoring of postmarketing clinical safety of Deng-
feng® shenmai Injection comes from the Study on Key
Technologies of Postmarketing Evaluation for Chinese
Medicine (No. 2009ZX09502-030), a national key
technological project "Major New Drug Develop-
ment" overseen by Yanming Xie, a researcher at the In-
stitute of Basic Research in Clinical Medicine. Current-
ly, the project has passed the review of Ethics Commit-
tee of Institute of Basic Research in Clinical Medicine
(Approval document No. 9-2), and completed interna-
tional registration at clinicaltrials. gov (ID:
NCT01612611). Meanwhile, the study has completed
the safety literature related to the injection, and fin-
ished the safety, effectiveness, and economics study
based on HIS data. The safety study based on the
Spontaneous reporting system data provided by the Na-
tional Adverse Drug Reaction Monitoring Center has
also been completed. Registry-based intensive hospital
monitoring of clinical safety of the drug has achieved
staged progress.
Leading institutions and 22 sub-centers have participat-
ed in the postmarketing clinical safety intensive hospi-
tal monitoring. The clinical monitoring of 30 000 pa-
tients will be completed by 2014. To further strength-
en quality control, from May-June 2013, the research
team organized experts to perform site inspections on
two leading institutions (the First Affiliated Hospital of
Guangzhou University of Chinese Medicine and the
First Affiliated Hospital of Tianjin Medical University)
and one sub-center (Anhui Tumor Hospital). The three
institutions completed monitoring over 3696 patients,
and reported six ADR/ADE cases. The audit experts
carefully examined the qualification of hospitals, re-
searchers, monitoring sheets, and original data, found
problems in the work, and drew a spot conclusion on
the auditing results of the hospitals.
SRS data analysis
Analysis4 of the 4220 cases reports involving ADR after
using Dengfeng® shenmai injection from 2005 to 2012
from State Adverse Drug Reaction Monitoring Center
shows that serious ADR account for 10.19% and new-
ly reported ADR account for 36.82%. Those who suf-
fer from ADR/ADE are mostly middle-aged and old
patients, and women are slightly more prone to ADEs
than men. ADR/ADE mainly include damage to the
central and peripheral nervous system, damage to the
skin, or systemic damage. The top 10 ADR symptoms
are shortness of breath, skin rashes, allergic reactions,
itching, chills, palpitations, flushing, dizziness, nausea,
and breathing difficulties. Bayesian confidence propaga-
tion neural network and proportional reporting ratio
methods were used to capture suspicious early warning
signals of ADR. Then, a test was made based on the re-
sults of the analysis using the propensity scoring meth-
od. The analysis found that shortness of breath, allergic
reaction, and flushing are early warning signals of
ADR to Shenmai injection. In addition, association
analysis and data mining were made on the factors re-
lated to ADR of Shenmai injection based on associa-
tion rules. The results show that patient ADR history
and ADR family history are most closely associated
with itching. Additionally, ADR family history is close-
ly related to excessive dosage, itching, nausea, and diffi-
culty in breathing.
Hospital information system (HIS) data analysis
An analysis5-7 was conducted on data including basic in-
formation, Western/TCM diagnostic information, doc-
tor information, and physical and chemical indicators
collected from HIS database and laboratory informa-
tion system database of inpatients from 18 domestic
hospitals Grade Ⅲ Level A. Information on indica-
tions population, death population, regimen, suspected
allergic reactions, and drug safety were analyzed with
descriptive statistics and statistical modeling oriented
to the whole population. There are two categories of
medicines used in combination with Shenmai injec-
tion. One category is conventional Western Medicine
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targeting the indications of Shenmai injection such as
nitroglycerin, insulin, penicillin, pantoprazole, or diaze-
pam. The other category is anti-allergy drugs such as
promethazine or vitamin C. For patients receiving a
dosage and treatment course in excess of the recom-
mended dosage and treatment courses, further analysis
was made on whether the medicine damages renal func-
tion. Analysis based on existing data found no damage
to renal function arising from use of Shenmai injection
at a dosage and a treatment course outside the recom-
mended dosage and treatment courses.
Literature analysis
There are 11 clinical ADR reports on Shenmai injec-
tion in the literature.1 The reports concern 21 cases, of
which no patients died, but six suffered serious adverse
reactions. Three patients experienced anaphylactic
shock, while three experienced a severe anaphylactoid
reaction. Among the 21 patients with adverse reac-
tions, the earliest occurred 3 min after commencement
of infusion, while the latest one occurred 3 days after
continuous infusion. The most common ADR symp-
toms of Shenmai injection reported are difficulty
breathing, facial flushing, nausea, vomiting, chest tight-
ness, skin itching, rash, and back pain.
Studies in the systematic review on the treatment of
acute myocardial infarction with Shenmai injection
show that use of the injection combined with conven-
tional treatment can reduce mortality of acute myocar-
dial infarction, morbidity of heart failure, and shock
and reinfarction in patients during hospitalization.8
However, the drug does not have an obvious effect on
improving coronary recanalization rate. However, these
results need to be further verified by high-quality ran-
domized controlled trial because of the poor quality of
the included studies. Systematic review did not find
any ADR/ADE occurring during the treatment of
acute myocardial infarction with Shenmai injection.
This review introduced the combination of active mon-
itoring with passive monitoring, combination of pro-
spective with retrospective studies, and combination of
literature studies with effect studies. We have reviewed
the information on ADR incidence rate to provide evi-
dence for the safety of Shenmai injection and to pro-
vide clinical, research, and production institutions with
an objective, reliable, and scientific basis for safe medi-
cation.
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